Fig. 1: Immunization-single B cell sequencing leads to development of potent monoclonal antibodies in both monospecific and bispecific forms. | Nature Communications

Fig. 1: Immunization-single B cell sequencing leads to development of potent monoclonal antibodies in both monospecific and bispecific forms.

From: Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Fig. 1

a Frequency distribution of immunoglobulin isotypes in SARS-CoV-2 Spike RBD (receptor-binding domain) immunized mice. (Top) Analysis of isotypes in both bone marrow and spleen in RBD-immunized C57BL/6 J mice (n = 1 mouse) (Bottom) Analysis of isotypes in RBD-immunized C57BL/6 J and BALB/c mice (n = 1 mouse). b CDR3 sequences of heavy and light chains of the top enriched antibody clones from RBD-his tag immunized C57BL/6 J mice (Top) and BALB/c mice (Bottom). CDR3: Complementarity-determining regions 3. c Octet measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones 2 and 6). The binding was particularly strong, thus that the dissociation stage was never observed in this BLI assay. d SPR measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones 2 and 6), using an NTA chip where the antigen (RBD) was fixed on the chip. e SPR measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones 2 and 6), a humanized mAb clone (Clone 13), and a bispecific mAb (Clone 16), using an Fc chip where antibodies were fixed on the chip. Source data and additional statistics for experiments are provided as a Source Data file.

Back to article page